Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07093281 · ClinicalTrials.gov registry record · Phase 4

Intranasal LAIV Mucosal Immunity Examination

A Phase 4 study, sponsored by University of Maryland, Baltimore.

Not yet
Registry status
Phase 4
Development phase
25
Enrollment target

NCT07093281 is a Phase 4 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07093281, a Phase 4 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.

NOT YET RECRUITING
Registry status
Phase 4
Development phase
25 participants
Enrollment target

Study Summary

The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines. Intranasal vaccines do not lead to the same changes in the blood that intramuscular vaccines do. Therefore, the investigators want to look at the function of immune (lymphoid) organs that are near the nose. The closest immune organs are the adenoids and tonsils. Mice do not have tonsils allowing for the investigators to answer these questions. Human lymphoid tissue will allow the investigators to better understand the molecular behavior of these cells in humans. The purpose of this protocol is to administer the FDA approved live attenuated influenza vaccine or no vaccine to patients undergoing adenoidectomy and/or tonsillectomy for obstructive sleep apnea prior to surgery and then collect the tissue (adenoid and/or tonsil tissue) that would normally be discarded from surgery. This will allow for improved understanding of what happens after vaccination.

Interventions

  • BIOLOGICAL Live Attenuated Influenza Vaccine

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2026-02
Est. Completion 2026-07
Phase Phase 4

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT07093281

The ClinicalTrials.gov registry entry for NCT07093281 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Live Attenuated Influenza Vaccine is the first listed.

NCT07093281 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07093281 about?

NCT07093281 is a clinical study titled "Intranasal LAIV Mucosal Immunity Examination". The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines. Intranasal vaccines do not lead to the same changes in the blood that intramuscular vaccines do. Therefore, the investigators want to look at the function of immune ...

What is the current status of trial NCT07093281?

This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2026-02. Estimated completion is 2026-07.

What interventions are being tested in trial NCT07093281?

The interventions under investigation include: Live Attenuated Influenza Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT07093281?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.